These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26836177)

  • 21. Alzheimer's disease prevention: from risk factors to early intervention.
    Crous-Bou M; Minguillón C; Gramunt N; Molinuevo JL
    Alzheimers Res Ther; 2017 Sep; 9(1):71. PubMed ID: 28899416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's disease.
    Scheltens P; Blennow K; Breteler MM; de Strooper B; Frisoni GB; Salloway S; Van der Flier WM
    Lancet; 2016 Jul; 388(10043):505-17. PubMed ID: 26921134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020.
    Hampel H; Lista S; Teipel SJ; Garaci F; Nisticò R; Blennow K; Zetterberg H; Bertram L; Duyckaerts C; Bakardjian H; Drzezga A; Colliot O; Epelbaum S; Broich K; Lehéricy S; Brice A; Khachaturian ZS; Aisen PS; Dubois B
    Biochem Pharmacol; 2014 Apr; 88(4):426-49. PubMed ID: 24275164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug discovery and the prevention of Alzheimer's disease.
    Fillit H
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S26-8. PubMed ID: 18631996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of lifestyle interventions on clinical and neuroimaging outcomes in elderly.
    Rolandi E; Frisoni GB; Cavedo E
    Ageing Res Rev; 2016 Jan; 25():1-12. PubMed ID: 26589097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates.
    Hroudová J; Fišar Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Aug; 134():111069. PubMed ID: 38917881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterizing Alzheimer's disease through metabolomics and investigating anti-Alzheimer's disease effects of natural products.
    Yi L; Liu W; Wang Z; Ren D; Peng W
    Ann N Y Acad Sci; 2017 Jun; 1398(1):130-141. PubMed ID: 28632966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological markers as outcome measures for Alzheimer's disease interventions--real problems and future possibilities.
    Takeda M; Okochi M; Tagami S; Tanaka T; Kudo T
    Int Psychogeriatr; 2007 Jun; 19(3):391-400. PubMed ID: 17391572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Research and standardization in Alzheimer's trials: reaching international consensus.
    Carrillo MC; Rowe CC; Szoeke C; Masters CL; Ames D; O'Meara T; Macaulay SL; Milner A; Ellis KA; Maruff P; Rainey-Smith SR; Martins RN; Bain LJ; Head RJ;
    Alzheimers Dement; 2013 Mar; 9(2):160-8. PubMed ID: 23266004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of Alzheimer's Disease: Lessons Learned and Applied.
    Galvin JE
    J Am Geriatr Soc; 2017 Oct; 65(10):2128-2133. PubMed ID: 28766695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.
    Hampel H; Schneider LS; Giacobini E; Kivipelto M; Sindi S; Dubois B; Broich K; Nisticò R; Aisen PS; Lista S
    Expert Rev Neurother; 2015 Jan; 15(1):83-105. PubMed ID: 25537424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.
    Gauthier S; Leuzy A; Racine E; Rosa-Neto P
    Prog Neurobiol; 2013 Nov; 110():102-13. PubMed ID: 23578568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease modifying trials in Alzheimer's disease: perspectives for the future.
    Vellas B; Coley N; Andrieu S
    J Alzheimers Dis; 2008 Oct; 15(2):289-301. PubMed ID: 18953115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention therapeutics of dementia.
    Schneider LS
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S122-30. PubMed ID: 18631988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What lessons can be learned from failed Alzheimer's disease trials?
    Toyn J
    Expert Rev Clin Pharmacol; 2015 May; 8(3):267-9. PubMed ID: 25860157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ethical Issues in the Development of Readiness Cohorts in Alzheimer's Disease Research.
    Milne R; Bunnik E; Tromp K; Bemelmans S; Badger S; Gove D; Maman M; Schermer M; Truyen L; Brayne C; Richard E
    J Prev Alzheimers Dis; 2017; 4(2):125-131. PubMed ID: 29186282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miRNAs as biofluid markers for diagnostics of Alzheimer's disease: recent status and perspectives.
    Kosikova N; Cente M; Cigankova V; Koson P; Filipcik P
    Gen Physiol Biophys; 2018 Sep; 37(5):495-514. PubMed ID: 30307401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease.
    Peters KR; Lynn Beattie B; Feldman HH; Illes J
    Prog Neurobiol; 2013 Nov; 110():114-23. PubMed ID: 23348495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer's disease.
    Goozee KG; Shah TM; Sohrabi HR; Rainey-Smith SR; Brown B; Verdile G; Martins RN
    Br J Nutr; 2016 Feb; 115(3):449-65. PubMed ID: 26652155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological aspects and anti-amyloid strategy for Alzheimer's dementia.
    Liščić RM
    Arh Hig Rada Toksikol; 2013 Dec; 64(4):603-8. PubMed ID: 24384767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.